


Lerigitazone

Cat. No.:	HY-117727		
CAS No.:	146062-44-4		
Molecular Formula:	C ₁₉ H ₂₀ N ₂ O ₄ S		
Molecular Weight:	372.44		
Target:	PPAR		
Pathway:	Cell Cycle/DNA Damage; Vitamin D Related/Nuclear Receptor		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description	Lerigitazone (MIN-102; Hydroxypioglitazone), a metabolite of pioglitazone. Lerigitazone PioOH is a PPAR γ agonist, stabilizes the PPAR γ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy. Lerigitazone binds to the PPAR γ C-terminal ligand-binding domain (LBD) with a K _i of 1.2 μ M. Lerigitazone induces transcriptional efficacy of the PPAR γ (LBD) with an EC ₅₀ of 680 nM ^[1] .
IC₅₀ & Target	Ki: 1.2 μ M (PPAR γ LBD); EC: 680 nM (PPAR γ LBD) (Lerigitazone) ^[1]

REFERENCES

[1]. Mosure SA, et al. Structural Basis of Altered Potency and Efficacy Displayed by a Major in Vivo Metabolite of the Antidiabetic PPAR γ Drug Pioglitazone. J Med Chem. 2019 Feb 28;62(4):2008-2023.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA